The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Therasse P. Measuring the clinical response. What does it mean? Eur. J. Cancer38(14), 1817–1823 (2002).
   PubMed Web of Science ®Google Scholar
• McHugh K, Kao S. Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology? Br. J. Radiol.76(907), 433–436 (2003).
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Hoffman JM, Johnson B et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res.11(8), 2785–2808 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon B, McArthur G, Cullinane C, Zalcberg J, Hicks R. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. BioDrugs17(5), 339–354 (2003).
   PubMed Web of Science ®Google Scholar
• Hicks RJ, Toner GC, Choong PF. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging5(1), 66–72 (2005).
   PubMedGoogle Scholar
• Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann. Oncol.16(4), 566–578 (2005).
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer47(1), 207–214 (1981).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer38(1), 388–394 (1976).
   PubMed Web of Science ®Google Scholar
• James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J. Natl Cancer Inst.91(6), 523–528 (1999).
   PubMed Web of Science ®Google Scholar
• Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch. Pathol. Lab. Med.101(1), 14–18 (1977).
   PubMed Web of Science ®Google Scholar
• Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J. Cancer Res. Clin. Oncol.106(Suppl.), 21–24 (1983).
   PubMed Web of Science ®Google Scholar
• Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J. Clin. Oncol.12(2), 423–431 (1994).
   PubMed Web of Science ®Google Scholar
• Raymond AK, Chawla SP, Carrasco CH et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin. Diagn. Pathol.4(3), 212–236 (1987).
   PubMed Web of Science ®Google Scholar
• Petrilli AS, Gentil FC, Epelman S et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer68(4), 733–737 (1991).
   PubMed Web of Science ®Google Scholar
• Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer69(3), 698–708 (1992).
   PubMed Web of Science ®Google Scholar
• Wuisman P, Enneking WF, Roesner A. Local growth and the prognosis of osteosarcoma. Int. Orthop.16(1), 55–58 (1992).
   PubMed Web of Science ®Google Scholar
• Bramwell VH, Burgers M, Sneath R et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J. Clin. Oncol.10(10), 1579–1591 (1992).
   PubMed Web of Science ®Google Scholar
• Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J. Clin. Oncol.15(1), 76–84 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bacci G, Picci P et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann. Oncol.8(8), 765–771 (1997).
   PubMed Web of Science ®Google Scholar
• Pochanugool L, Subhadharaphandou T, Dhanachai M et al. Prognostic factors among 130 patients with osteosarcoma. Clin. Orthop. Relat. Res.(345), 206–214 (1997).
   Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol.20(3), 776–790 (2002).
   PubMed Web of Science ®Google Scholar
• Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A-year experience of a European Cooperative Trial. Cancer61(1), 23–32 (1988).
   PubMed Web of Science ®Google Scholar
• Delepine N, Delepine G, Cornille H et al. Prognostic factors in patients with localized Ewing’s sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J. Chemother.9(5), 352–363 (1997).
   PubMed Web of Science ®Google Scholar
• Wunder JS, Paulian G, Huvos AG et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J. Bone Joint Surg. Am.80(7), 1020–1033 (1998).
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Ahrens S, Dunst J et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer85(4), 869–877 (1999).
   PubMed Web of Science ®Google Scholar
• Rosito P, Mancini AF, Rondelli R et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer86(3), 421–428 (1999).
   PubMed Web of Science ®Google Scholar
• Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J. Clin. Oncol.19(6), 1818–1829 (2001).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Ferrari S et al. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol.45(4), 469–475 (2006).
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol.19(13), 3203–3209 (2001).
   PubMed Web of Science ®Google Scholar
• Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med.16(3), 210–224 (1975).
   PubMed Web of Science ®Google Scholar
• Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br. J. Biomed. Sci.56(4), 285–292 (1999).
   PubMed Web of Science ®Google Scholar
• Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci.57(2), 170–178 (2000).
   PubMed Web of Science ®Google Scholar
• Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science235(4795), 1492–1495 (1987).
   PubMed Web of Science ®Google Scholar
• Huber BE, Cordingley MG. Expression and phenotypic alterations caused by an inducible transforming ras oncogene introduced into rat liver epithelial cells. Oncogene3(3), 245–256 (1988).
   PubMed Web of Science ®Google Scholar
• Persons DA, Schek N, Hall BL, Finn OJ. Increased expression of glycolysis-associated genes in oncogene-transformed and growth-accelerated states. Mol. Carcinog.2(2), 88–94 (1989).
   PubMed Web of Science ®Google Scholar
• Osthus RC, Shim H, Kim S et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem.275(29), 21797–21800 (2000).
   PubMed Web of Science ®Google Scholar
• Shawver LK, Olson SA, White MK, Weber MJ. Degradation and biosynthesis of the glucose transporter protein in chicken embryo fibroblasts transformed by the src oncogene. Mol. Cell Biol.7(6), 2112–2118 (1987).
   PubMed Web of Science ®Google Scholar
• White MK, Weber MJ. Transformation by the src oncogene alters glucose transport into rat and chicken cells by different mechanisms. Mol. Cell Biol.8(1), 138–144 (1988).
   PubMed Web of Science ®Google Scholar
• Scimeca JC, Ballotti R, Alengrin F et al. Metabolic effects induced by epidermal growth factor (EGF) in cells expressing EGF receptor mutants. J. Biol. Chem.264(12), 6831–6835 (1989).
   PubMed Web of Science ®Google Scholar
• Sistonen L, Holtta E, Lehvaslaiho H, Lehtola L, Alitalo K. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J. Cell Biol.109(5), 1911–1919 (1989).
   PubMed Web of Science ®Google Scholar
• Weiland M, Bahr F, Hohne M et al. The signaling potential of the receptors for insulin and insulin-like growth factor I (IGF-I) in 3T3-L1 adipocytes: comparison of glucose transport activity, induction of oncogene c-fos, glucose transporter mRNA, and DNA-synthesis. J. Cell Physiol.149(3), 428–435 (1991).
   PubMed Web of Science ®Google Scholar
• Barthel A, Okino ST, Liao J et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem.274(29), 20281–20286 (1999).
   PubMed Web of Science ®Google Scholar
• Frauwirth KA, Riley JL, Harris MH et al. The CD28 signaling pathway regulates glucose metabolism. Immunity16(6), 769–777 (2002).
   PubMed Web of Science ®Google Scholar
• Barata JT, Silva A, Brandao JG et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med.200(5), 659–669 (2004).
   PubMed Web of Science ®Google Scholar
• VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol. Cancer Ther.3(12), 1605–1613 (2004).
   PubMed Web of Science ®Google Scholar
• Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem.269(38), 23757–23763 (1994).
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Bauer DE, Buzzai M et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res.64(11), 3892–3899 (2004).
   PubMed Web of Science ®Google Scholar
• Sakata K, Kato S, Fox JC, Shigemori M, Morimatsu M. Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J. Neuropathol. Exp. Neurol.61(11), 975–983 (2002).
   PubMed Web of Science ®Google Scholar
• Feng Z, Hu W, de Stanchina E et al. The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res.67(7), 3043–3053 (2007).
   PubMed Web of Science ®Google Scholar
• Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med.47(6), 1059–1066 (2006).
   PubMed Web of Science ®Google Scholar
• Larson SM, Erdi Y, Akhurst T et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin. Positron Imaging2(3), 159–171 (1999).
   PubMedGoogle Scholar
• Basu S, Zaidi H, Houseni M et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin. Nucl. Med.37(3), 223–239 (2007).
   PubMed Web of Science ®Google Scholar
• Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J. Nucl. Med.31(3), 337–342 (1990).
   PubMed Web of Science ®Google Scholar
• Wells P, Gunn RN, Alison M et al. Assessment of proliferation in vivo using 2-[11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res.62(20), 5698–5702 (2002).
   PubMed Web of Science ®Google Scholar
• Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med.4(11), 1334–1336 (1998).
   PubMed Web of Science ®Google Scholar
• Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med.43(9), 1210–1217 (2002).
   PubMed Web of Science ®Google Scholar
• Buck AK, Schirrmeister H, Hetzel M et al. 3-deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res.62(12), 3331–3334 (2002).
   PubMed Web of Science ®Google Scholar
• Cobben DC, Elsinga PH, Suurmeijer AJ et al. Detection and grading of soft tissue sarcomas of the extremities with 18F-3´-fluoro-3´-deoxy-L-thymidine. Clin. Cancer Res.10(5), 1685–1690 (2004).
   PubMed Web of Science ®Google Scholar
• Been LB, Suurmeijer AJ, Elsinga PH et al. 18F -fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J. Nucl. Med.48(3), 367–372 (2007).
   PubMed Web of Science ®Google Scholar
• Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J. Nucl. Med.38(6), 842–847 (1997).
   PubMedGoogle Scholar
• Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med.39(6), 990–995 (1998).
   PubMed Web of Science ®Google Scholar
• DeGrado TR, Coleman RE, Wang S et al. Synthesis and evaluation of 18F -labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res.61(1), 110–117 (2001).
   PubMed Web of Science ®Google Scholar
• Hara T, Kosaka N, Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J. Nucl. Med.43(2), 187–199 (2002).
   PubMed Web of Science ®Google Scholar
• Bolster JM, Vaalburg W, Paans AM et al. Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J. Nucl. Med.12(7), 321–324 (1986).
   PubMedGoogle Scholar
• Wienhard K, Herholz K, Coenen HH et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J. Nucl. Med.32(7), 1338–1346 (1991).
   PubMed Web of Science ®Google Scholar
• Inoue T, Tomiyoshi K, Higuichi T et al. Biodistribution studies on L-3-[fluorine-18]fluoro-α-methyl tyrosine: a potential tumor-detecting agent. J. Nucl. Med.39(4), 663–667 (1998).
   PubMed Web of Science ®Google Scholar
• Wester HJ, Herz M, Weber W et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J. Nucl. Med.40(1), 205–212 (1999).
   PubMed Web of Science ®Google Scholar
• Kubota K, Ishiwata K, Kubota R et al. Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-L-methionine. J. Nucl. Med.37(2), 320–325 (1996).
   PubMedGoogle Scholar
• van Ginkel RJ, Kole AC, Nieweg OE et al. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J. Nucl. Med.40(2), 262–267 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang H, Yoshikawa K, Tamura K et al. [11C]methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin. Cancer Res.10(5), 1764–1772 (2004).
   PubMed Web of Science ®Google Scholar
• Chang CH, Wang HE, Wu SY et al. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res.26(2A), 917–925 (2006).
   PubMed Web of Science ®Google Scholar
• Pauleit D, Zimmermann A, Stoffels G et al.18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J. Nucl. Med.47(2), 256–261 (2006).
   PubMed Web of Science ®Google Scholar
• Glaser M, Collingridge DR, Aboagye EO et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot.58(1), 55–62 (2003).
   PubMed Web of Science ®Google Scholar
• Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl. Radiat. Isot.58(2), 201–207 (2003).
   PubMed Web of Science ®Google Scholar
• Fujibayashi Y, Taniuchi H, Yonekura Y et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med.38(7), 1155–1160 (1997).
   PubMed Web of Science ®Google Scholar
• Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl. Radiat. Isot.54(1), 73–80 (2001).
   PubMed Web of Science ®Google Scholar
• Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg. Med. Chem.9(3), 665–675 (2001).
   PubMed Web of Science ®Google Scholar
• Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys.17(5), 985–991 (1989).
   PubMed Web of Science ®Google Scholar
• Koh WJ, Rasey JS, Evans ML et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys.22(1), 199–212 (1992).
   PubMed Web of Science ®Google Scholar
• Rajendran JG, Wilson DC, Conrad EU et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur. J. Nucl. Med. Mol. Imaging30(5), 695–704 (2003).
   PubMed Web of Science ®Google Scholar
• Sorger D, Patt M, Kumar P et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol.30(3), 317–326 (2003).
   PubMed Web of Science ®Google Scholar
• Piert M, Machulla HJ, Picchio M et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J. Nucl. Med.46(1), 106–113 (2005).
   PubMed Web of Science ®Google Scholar
• Reischl G, Dorow DS, Cullinane C et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA – first small animal PET results. J. Pharm. Pharm. Sci.10(2), 203–211 (2007).
   PubMed Web of Science ®Google Scholar
• Dahlbom M, Hoffman EJ, Hoh CK et al. Whole-body positron emission tomography: part I. Methods and performance characteristics. J. Nucl. Med.33(6), 1191–1199 (1992).
   PubMed Web of Science ®Google Scholar
• Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med.41(8), 1369–1379 (2000).
   PubMed Web of Science ®Google Scholar
• Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J. Nucl. Med.42(5 Suppl), 1–93S (2001).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J. Nucl. Med.44(5), 717–724 (2003).
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Groen H, Jager PL et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat. Rev.30(1), 83–101 (2004).
   PubMed Web of Science ®Google Scholar
• Brown FM, Fletcher CD. Problems in grading soft tissue sarcomas. Am. J. Clin. Pathol.114(Suppl.), S82–S89 (2000).
   Google Scholar
• Oliveira AM, Nascimento AG. Grading in soft tissue tumors: principles and problems. Skeletal Radiol.30(10), 543–559 (2001).
   PubMed Web of Science ®Google Scholar
• Shives TC. Biopsy of soft-tissue tumors. Clin. Orthop. Relat. Res.(289), 32–35 (1993).
   Google Scholar
• Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin. Cancer Res.4(5), 1215–1220 (1998).
   PubMed Web of Science ®Google Scholar
• Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res.6(4), 1279–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Adler LP, Blair HF, Makley JT et al. Noninvasive grading of musculoskeletal tumors using PET. J. Nucl. Med.32(8), 1508–1512 (1991).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Heymer B et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J. Nucl. Med.26(6), 599–605 (1999).
   Google Scholar
• Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J. Nucl. Med.41(10), 1695–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg.231(3), 380–386 (2000).
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G et al. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res.21(5), 3609–3614 (2001).
   PubMed Web of Science ®Google Scholar
• Lee FY, Yu J, Chang SS, Fawwaz R, Parisien MV. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. J. Bone Joint Surg. Am.86-A(12), 2677–2685 (2004).
   Google Scholar
• Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging31(2), 189–195 (2004).
   PubMed Web of Science ®Google Scholar
• Tateishi U, Yamaguchi U, Seki K et al. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging33(6), 683–691 (2006).
   PubMed Web of Science ®Google Scholar
• Kole AC, Nieweg OE, van Ginkel RJ et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann. Surg. Oncol.4(1), 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Lucas JD, O’Doherty MJ, Cronin BF et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br. J. Surg.86(4), 550–556 (1999).
   PubMed Web of Science ®Google Scholar
• Hain SF, O’Doherty MJ, Bingham J, Chinyama C, Smith MA. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl. Med. Commun.24(11), 1139–1143 (2003).
   Google Scholar
• Eary JF, O’Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur. J. Nucl. Med. Mol. Imaging29(9), 1149–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer103(2), 339–348 (2005).
   PubMed Web of Science ®Google Scholar
• Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging33(11), 1290–1295 (2006).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol.23(34), 8828–8834 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann. Surg.241(2), 286–294 (2005).
   PubMed Web of Science ®Google Scholar
• Franzius C, Bielack S, Flege S et al. Prognostic significance of 18F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J. Nucl. Med.43(8), 1012–1017 (2002).
   PubMed Web of Science ®Google Scholar
• Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur. J. Nucl. Med.27(9), 1305–1311 (2000).
   PubMedGoogle Scholar
• Schirrmeister H, Guhlmann A, Elsner K et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J. Nucl. Med.40(10), 1623–1629 (1999).
   PubMed Web of Science ®Google Scholar
• Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann. Oncol.12(4), 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• Lucas JD, O’Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J. Bone Joint Surg. Br.80(3), 441–447 (1998).
   PubMedGoogle Scholar
• Klem ML, Grewal RK, Wexler LH et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J. Pediatr. Hematol. Oncol.29(1), 9–14 (2007).
   PubMed Web of Science ®Google Scholar
• Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol.13(1), 157–160 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin. Nucl. Med.28(10), 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia R, Kim EE, Wong FC et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J. Nucl. Med.37(9), 1476–1479 (1996).
   PubMed Web of Science ®Google Scholar
• Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res.19(2B), 1343–1349 (1999).
   PubMed Web of Science ®Google Scholar
• Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am. J. Roentgenol.179(5), 1145–1150 (2002).
   PubMed Web of Science ®Google Scholar
• Hustinx R, Smith RJ, Benard F et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur. J. Nucl. Med.26(10), 1345–1348 (1999).
   PubMedGoogle Scholar
• Zhuang H, Pourdehnad M, Lambright ES et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med.42(9), 1412–1417 (2001).
   PubMed Web of Science ®Google Scholar
• van Waarde A, Cobben DC, Suurmeijer AJ et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J. Nucl. Med.45(4), 695–700 (2004).
   PubMed Web of Science ®Google Scholar
• Kubota K, Furumoto S, Iwata R et al. Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann. Nucl. Med.20(8), 527–533 (2006).
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Danesi R et al. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br. J. Cancer92(4), 681–689 (2005).
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Taxman DJ, Hunter D et al. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin. Cancer Res.8(7), 2091–2099 (2002).
   PubMed Web of Science ®Google Scholar
• Kim SH, Juhnn YS, Song YS. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann. NY Acad. Sci.1095, 82–89 (2007).
   PubMed Web of Science ®Google Scholar
• Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res.60(19), 5451–5455 (2000).
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Uranchimeg B, Sordet O et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res.64(4), 1475–1482 (2004).
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chinratanalab W, Ritter CA et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res.62(14), 4132–4141 (2002).
   PubMed Web of Science ®Google Scholar
• Le XF, Lammayot A, Gold D et al. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J. Biol. Chem.280(3), 2092–2104 (2005).
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ikehara Y, Kodera Y et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br. J. Cancer95(11), 1504–1513 (2006).
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer13(2), 137–144 (2006).
   PubMedGoogle Scholar
• Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res.62(12), 3515–3520 (2002).
   PubMed Web of Science ®Google Scholar
• Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int. J. Cancer107(2), 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• Glass-Marmor L, Beitner R. Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Eur. J. Pharmacol.370(2), 195–199 (1999).
   PubMed Web of Science ®Google Scholar
• Barnes K, McIntosh E, Whetton AD et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene24(20), 3257–3267 (2005).
   PubMed Web of Science ®Google Scholar
• Boren J, Cascante M, Marin S et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem.276(41), 37747–37753 (2001).
   PubMed Web of Science ®Google Scholar
• Takei T, Kuge Y, Zhao S et al. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J. Nucl. Med.46(5), 794–799 (2005).
   PubMed Web of Science ®Google Scholar
• Su H, Bodenstein C, Dumont RA et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res.12(19), 5659–5667 (2006).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J. Nucl. Med.40(10), 1637–1643 (1999).
   PubMed Web of Science ®Google Scholar
• Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin. Nucl. Med.25(11), 874–881 (2000).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer94(12), 3277–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Nair N, Ali A, Green AA et al. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET Scans. Clin. Positron Imaging3(2), 79–83 (2000).
   PubMedGoogle Scholar
• Jones DN, McCowage GB, Sostman HD et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J. Nucl. Med.37(9), 1438–1444 (1996).
   PubMed Web of Science ®Google Scholar
• van Ginkel RJ, Hoekstra HJ, Pruim J et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J. Nucl. Med.37(6), 984–990 (1996).
   PubMedGoogle Scholar
• Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer35(13), 1773–1782 (1999).
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Alsner J, Keller J et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer84(8), 1070–1075 (2001).
   PubMed Web of Science ®Google Scholar
• Maseide K, Kandel RA, Bell RS et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin. Cancer Res.10(13), 4464–4471 (2004).
   PubMed Web of Science ®Google Scholar
• Shintani K, Matsumine A, Kusuzaki K et al. Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch.449(6), 673–681 (2006).
   PubMed Web of Science ®Google Scholar
• Francis P, Namlos HM, Muller C et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics8, 73 (2007).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307(5706), 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Del Guerra A, Belcari N. Advances in animal PET scanners. Q. J. Nucl. Med.46(1), 35–47 (2002).
   PubMedGoogle Scholar
• Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging. current technology and perspectives for oncological imaging. Eur. J. Cancer38(16), 2173–2188 (2002).
   PubMed Web of Science ®Google Scholar
• Leyton J, Latigo JR, Perumal M et al. Early detection of tumor response to chemotherapy by 3´-deoxy-3´-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res.65(10), 4202–4210 (2005).
   PubMed Web of Science ®Google Scholar
• Pichler BJ, Judenhofer MS, Catana C et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J. Nucl. Med.47(4), 639–647 (2006).
   PubMed Web of Science ®Google Scholar
• Catana C, Wu Y, Judenhofer MS et al. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J. Nucl. Med.47(12), 1968–1976 (2006).
   PubMed Web of Science ®Google Scholar